Long term antipsychotic treatment does not alter metabolite concentrations in rat striatum: An in vivo magnetic resonance spectroscopy study

Schizophrenia Research

Volumn 128, Issue 1-3, 2011, Pages 83-90

  Lindquist, Diana M ^a   Dunn, R Scott ^a   Cecil, Kim M ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Antipsychotics; Brain; Magnetic resonance spectroscopy; N acetyl aspartate; Schizophrenia

Indexed keywords

CHOLINE; CLOZAPINE; CREATINE; GLUTAMIC ACID; GLUTAMINE; HALOPERIDOL; INOSITOL; N ACETYLASPARTIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CORPUS STRIATUM; DRUG DOSE COMPARISON; DRUG MEGADOSE; IN VIVO STUDY; LONG TERM CARE; LOW DRUG DOSE; MALE; METABOLITE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; SCHIZOPHRENIA;

ANALYSIS OF VARIANCE; ANIMALS; ANTIPSYCHOTIC AGENTS; ASPARTIC ACID; CHOLINE; CLOZAPINE; CORPUS STRIATUM; CREATINE; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUTAMIC ACID; HALOPERIDOL; MAGNETIC RESONANCE SPECTROSCOPY; MALE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 79955464224     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2011.02.019     Document Type: Article

References (44)

1. Assis L.C., Scaini G., Di-Pietro P.B., Castro A.A., Comim C.M., Streck E.L., Quevedo J. Effect of antipsychotics on creatine kinase activity in rat brain. Basic Clin. Pharmacol. Toxicol. 2007, 101(5):315-319.
2. Bartzokis G., Lu P.H., Stewart S.B., Oluwadara B., Lucas A.J., Pantages J., Pratt E., Sherin J.E., Altshuler L.L., Mintz J., Gitlin M.J., Subotnik K.L., Nuechterlein K.H. In vivo evidence of differential impact of typical and atypical antipsychotics on intracortical myelin in adults with schizophrenia. Schizophr. Res. 2009, 113(2-3):322-331.
3. Bertolino A., Callicott J.H., Mattay V.S., Weidenhammer K.M., Rakow R., Egan M.F., Weinberger D.R. The effect of treatment with antipsychotic drugs on brain N-acetylaspartate measures in patients with schizophrenia. Biol. Psychiatry 2001, 49(1):39-46.
4. Brugger S., Davis J.M., Leucht S., Stone J.M. Proton magnetic resonance spectroscopy and illness stage in schizophrenia - a systematic review and meta-analysis. Biol. Psychiatry 2011, 69(5):495-503.
5. Bustillo J.R., Lauriello J., Rowland L.M., Jung R.E., Petropoulos H., Hart B.L., Blanchard J., Keith S.J., Brooks W.M. Effects of chronic haloperidol and clozapine treatments on frontal and caudate neurochemistry in schizophrenia. Psychiatry Res. 2001, 107(3):135-149.
6. Bustillo J.R., Lauriello J., Rowland L.M., Thomson L.M., Petropoulos H., Hammond R., Hart B., Brooks W.M. Longitudinal follow-up of neurochemical changes during the first year of antipsychotic treatment in schizophrenia patients with minimal previous medication exposure. Schizophr. Res. 2002, 58(2-3):313-321.
7. Bustillo J., Wolff C., Myers-y-Gutierrez A., Dettmer T.S., Cooper T.B., Allan A., Lauriello J., Valenzuela C.F. Treatment of rats with antipsychotic drugs: lack of an effect on brain N-acetyl aspartate levels. Schizophr. Res. 2004, 66(1):31-39.
8. Bustillo J., Barrow R., Paz R., Tang J., Seraji-Bozorgzad N., Moore G.J., Bolognani F., Lauriello J., Perrone-Bizzozero N., Galloway M.P. Long-term treatment of rats with haloperidol: lack of an effect on brain N-acetyl aspartate levels. Neuropsychopharmacology 2006, 31(4):751-756.
9. Bustillo J.R., Rowland L.M., Jung R., Brooks W.M., Qualls C., Hammond R., Hart B., Lauriello J. Proton magnetic resonance spectroscopy during initial treatment with antipsychotic medication in schizophrenia. Neuropsychopharmacology 2008, 33(10):2456-2466.
10. Bustillo J.R., Rowland L.M., Mullins P., Jung R., Chen H., Qualls C., Hammond R., Brooks W.M., Lauriello J. (1)H-MRS at 4Tesla in minimally treated early schizophrenia. Mol. Psychiatry 2010, 15(6):629-636.
11. Chang L., Friedman J., Ernst T., Zhong K., Tsopelas N.D., Davis K. Brain metabolite abnormalities in the white matter of elderly schizophrenic subjects: implication for glial dysfunction. Biol. Psychiatry 2007, 62(12):1396-1404.
12. Choe B.Y., Suh T.S., Shinn K.S., Lee C.W., Lee C., Paik I.H. Observation of metabolic changes in chronic schizophrenia after neuroleptic treatment by in vivo hydrogen magnetic resonance spectroscopy. Invest. Radiol. 1996, 31(6):345-352.
13. Critchlow H.M., Maycox P.R., Skepper J.N., Krylova O. Clozapine and haloperidol differentially regulate dendritic spine formation and synaptogenesis in rat hippocampal neurons. Mol. Cell. Neurosci. 2006, 32(4):356-365.
14. Ende G., Braus D.F., Walter S., Weber-Fahr W., Henn F.A. Multiregional 1H-MRSI of the hippocampus, thalamus, and basal ganglia in schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 2003, 253(1):9-15.
15. Ertugrul A., Volkan-Salanci B., Basar K., Karli Oguz K., Demir B., Ergun E.L., Senturk S., Erbas B., Cila A., Ulug B. The effect of clozapine on regional cerebral blood flow and brain metabolite ratios in schizophrenia: relationship with treatment response. Psychiatry Res. 2009, 174(2):121-129.
16. Fannon D., Simmons A., Tennakoon L., O'Ceallaigh S., Sumich A., Doku V., Shew C., Sharma T. Selective deficit of hippocampal N-acetylaspartate in antipsychotic-naive patients with schizophrenia. Biol. Psychiatry 2003, 54(6):587-598.
17. Harte M.K., Bachus S.B., Reynolds G.P. Increased N-acetylaspartate in rat striatum following long-term administration of haloperidol. Schizophr. Res. 2005, 75(2-3):303-308.
18. Heimberg C., Komoroski R.A., Lawson W.B., Cardwell D., Karson C.N. Regional proton magnetic resonance spectroscopy in schizophrenia and exploration of drug effect. Psychiatry Res. 1998, 83(2):105-115.
19. Ho B.C., Andreasen N.C., Ziebell S., Pierson R., Magnotta V. Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. Arch. Gen. Psychiatry 2011, 68(2):128-137.
20. Kapur S., Wadenberg M.L., Remington G. Are animal studies of antipsychotics appropriately dosed? Lessons from the bedside to the bench. Can. J. Psychiatry 2000, 45(3):241-246.
21. Kapur S., VanderSpek S.C., Brownlee B.A., Nobrega J.N. Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J. Pharmacol. Exp. Ther. 2003, 305(2):625-631.
22. Khan M.M., Parikh V.V., Mahadik S.P. Antipsychotic drugs differentially modulate apolipoprotein D in rat brain. J. Neurochem. 2003, 86(5):1089-1100.
23. Lindquist D.M., Hawk R.M., Karson C.N., Komoroski R.A. Effects of antipsychotic drugs on metabolite ratios in rat brain in vivo. Magn. Reson. Med. 2000, 43(3):355-358.
24. McLoughlin G.A., Ma D., Tsang T.M., Jones D.N., Cilia J., Hill M.D., Robbins M.J., Benzel I.M., Maycox P.R., Holmes E., Bahn S. Analyzing the effects of psychotropic drugs on metabolite profiles in rat brain using 1H NMR spectroscopy. J. Proteome Res. 2009, 8(4):1943-1952.
25. Olbrich H.M., Valerius G., Rusch N., Buchert M., Thiel T., Hennig J., Ebert D., Van Elst L.T. Frontolimbic glutamate alterations in first episode schizophrenia: evidence from a magnetic resonance spectroscopy study. World J. Biol. Psychiatry 2008, 9(1):59-63.
26. Pae C.U., Choe B.Y., Joo R.H., Lim H.K., Kim T.S., Yoo S.S., Choi B.G., Kim J.J., Lee S.J., Lee C., Paik I.H., Lee C.U. Neuronal dysfunction of the frontal lobe in schizophrenia. Neuropsychobiology 2004, 50(3):211-215.
27. Pani L., Pira L., Marchese G. Antipsychotic efficacy: relationship to optimal D2-receptor occupancy. Eur. Psychiatry 2007, 22(5):267-275.
28. Perez-Costas E., Guidetti P., Melendez-Ferro M., Kelley J.J., Roberts R.C. Neuroleptics and animal models: feasibility of oral treatment monitored by plasma levels and receptor occupancy assays. J. Neural Transm. 2008, 115(5):745-753.
29. Provencher S.W. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn. Reson. Med. 1993, 30(6):672-679.
30. Richtand N.M., Welge J.A., Logue A.D., Keck P.E., Strakowski S.M., McNamara R.K. Dopamine and serotonin receptor binding and antipsychotic efficacy. Neuropsychopharmacology 2007, 32(8):1715-1726.
31. Ross A.J., Sachdev P.S. Magnetic resonance spectroscopy in cognitive research. Brain Res. Brain Res. Rev. 2004, 44(2-3):83-102.
32. Shirayama Y., Obata T., Matsuzawa D., Nonaka H., Kanazawa Y., Yoshitome E., Ikehira H., Hashimoto K., Iyo M. Specific metabolites in the medial prefrontal cortex are associated with the neurocognitive deficits in schizophrenia: a preliminary study. Neuroimage 2010, 49(3):2783-2790.
33. Steen R.G., Hamer R.M., Lieberman J.A. Measurement of brain metabolites by 1H magnetic resonance spectroscopy in patients with schizophrenia: a systematic review and meta-analysis. Neuropsychopharmacology 2005, 30(11):1949-1962.
34. Stone J.M., Day F., Tsagaraki H., Valli I., McLean M.A., Lythgoe D.J., O'Gorman R.L., Barker G.J., McGuire P.K. Glutamate dysfunction in people with prodromal symptoms of psychosis: relationship to gray matter volume. Biol. Psychiatry 2009, 66(6):533-539.
35. Streck E.L., Rezin G.T., Barbosa L.M., Assis L.C., Grandi E., Quevedo J. Effect of antipsychotics on succinate dehydrogenase and cytochrome oxidase activities in rat brain. Naunyn Schmiedebergs Arch. Pharmacol. 2007, 376(1-2):127-133.
36. Szulc A., Galinska B., Tarasow E., Dzienis W., Kubas B., Konarzewska B., Walecki J., Alathiaki A.S., Czernikiewicz A. The effect of risperidone on metabolite measures in the frontal lobe, temporal lobe, and thalamus in schizophrenic patients. A proton magnetic resonance spectroscopy (1H MRS). Pharmacopsychiatry 2005, 38(5):214-219.
37. Szulc A., Galinska B., Tarasow E., Kubas B., Dzienis W., Konarzewska B., Poplawska R., Tomczak A.A., Czernikiewicz A., Walecki J. N-acetylaspartate (NAA) levels in selected areas of the brain in patients with chronic schizophrenia treated with typical and atypical neuroleptics: a proton magnetic resonance spectroscopy (1H MRS) study. Med. Sci. Monit. 2007, 13(Suppl 1):17-22.
38. Tayoshi S., Sumitani S., Taniguchi K., Shibuya-Tayoshi S., Numata S., Iga J., Nakataki M., Ueno S., Harada M., Ohmori T. Metabolite changes and gender differences in schizophrenia using 3-Tesla proton magnetic resonance spectroscopy (1H-MRS). Schizophr. Res. 2009, 108(1-3):69-77.
39. Theberge J., Al-Semaan Y., Drost D.J., Malla A.K., Neufeld R.W., Bartha R., Manchanda R., Menon R., Densmore M., Schaefer B., Williamson P.C. Duration of untreated psychosis vs. N-acetylaspartate and choline in first episode schizophrenia: a 1H magnetic resonance spectroscopy study at 4.0 Tesla. Psychiatry Res. 2004, 131(2):107-114.
40. Theberge J., Williamson K.E., Aoyama N., Drost D.J., Manchanda R., Malla A.K., Northcott S., Menon R.S., Neufeld R.W., Rajakumar N., Pavlosky W., Densmore M., Schaefer B., Williamson P.C. Longitudinal grey-matter and glutamatergic losses in first-episode schizophrenia. Br. J. Psychiatry 2007, 191:325-334.
41. Thomas E.A., Yao J.K. Clozapine specifically alters the arachidonic acid pathway in mice lacking apolipoprotein D. Schizophr. Res. 2007, 89(1-3):147-153.
42. Vernon A.C., Natesan S., Modo M., Kapur S. Effect of chronic antipsychotic treatment on brain structure: a serial magnetic resonance imaging study with ex vivo and postmortem confirmation. Biol. Psychiatry. 2010, Electronic publication ahead of print. doi:10.1016/j.biopsych.2010.11.010.
43. Yoo S.Y., Yeon S., Choi C.H., Kang D.H., Lee J.M., Shin N.Y., Jung W.H., Choi J.S., Jang D.P., Kwon J.S. Proton magnetic resonance spectroscopy in subjects with high genetic risk of schizophrenia: investigation of anterior cingulate, dorsolateral prefrontal cortex and thalamus. Schizophr. Res. 2009, 111(1-3):86-93.
44. Zhang W., Bymaster F.P. The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D1, D2, D3, 5HT2A and muscarinic receptors. Psychopharmacology (Berl) 1999, 141(3):267-278.